2. Metabolic Enzyme/Protease Apoptosis
  3. Angiotensin-converting Enzyme (ACE) Apoptosis
  4. Moexipril

Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects-.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Moexipril hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Moexipril Chemical Structure

Moexipril Chemical Structure

CAS No. : 103775-10-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Moexipril:

Other Forms of Moexipril:

Moexipril Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects[1]-[4].

IC50 & Target

IC50: 2.1 nM (purified ACE from rabbit lung), 1.75 nM (ACE in rat plasma)[3]
In Vitro

Moexipril is devoid of anti-inflammatory properties and has no effect on platelet function[2].
Moexipril hydrolyzes to Moexiprilat, and Moexiprilat inhibits ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50s of 2.6 nM and 4.9 nM, respectively[2].
Moexipril (0.01 nM-0.1 mM) exhibits high potency against both ACE in rats plasma and purified ACE from rabbit lung, with IC50s of 1.75 nM and 2.1 nM, respectively[3].
Moexipril (0-100 μM, 24 h) significantly reduced the percentage of damaged neurons in a dose-dependent manner[4].
Moexipril (0-100 μM, 24 h) significantly attenuates Fe2+/3+-induced neurotoxicity[4].
Moexipril dose not cause significant changes in the percentage of apoptotic neurons[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Moexipril Related Antibodies
In Vivo

Moexipril can not cross the blood-brain barrier[1].
Moexipril (3 mg/kg, 30 mg/kg and 10 mg/kg; p.o.; once daily; 5 days) exhibits a dose-dependent and antihypertensive effects in renal hypertensive rats, spontaneously hypertensive rats and perinephritic hypertensive dogs, respectively[3].
Moexipril (0.3 mg/kg, i.p.) significantly reduces the infarct area on the mouse brain surface in NMRI mice[4].
Moexipril (0.1 mg/kg, i.p.) significantly attenuates the cortical infarct volume in Long-Evans rats[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Spontaneously hypertensive rats[3]
Dosage: 30 mg/kg
Administration: Oral gavage; once daily; 5 days
Result: Caused a progressive lowering of mean blood pressure from pretreatment values of 180 +/- 7 mmHg to a trough on day 4 of 127 +/- 4 mmHg.
Dose-dependently decreased arterial blood pressure, and inhibited plasma and tissue ACE activity.
Animal Model: Renal hypertensive rats[3]
Dosage: 0.03-10 mg/kg
Administration: Oral gavage; once daily; 5 days
Result: Caused a dose-dependent decrease in blood pressure with a threshold dose of 0.3 mg/kg.
Lowered mean blood pressure by about 70 mmHg of 3 mg/kg.
Animal Model: Perinephritic hypertensive dogs[3]
Dosage: 10 mg/kg
Administration: Oral gavage; once daily; 5 days
Result: Caused a drop of mean blood pressure by 25 mmHg from pre-treatment control, which persisted for 24 h, by a rapid onset and a long duration of action.
Animal Model: NMRI mice (male, Permanent focal ischemia)[4]
Dosage: 0, 0.03, 0.3, and 3 mg/kg
Administration: Intraperitoneal injection (1 h before middle cerebral artery occlusion)
Result: Significantly reduced the infarct area on the mouse brain surface with a dose of 0.3 mg/kg, and other doses were not effective.
Animal Model: Long-Evans rats (male, Permanent focal ischemia)[4]
Dosage: 0, 0.01, 0.1 mg/kg
Administration: Intraperitoneal injection (1 h before middle cerebral artery occlusion)
Result: Significantly attenuated the cortical infarct volume from 114.4 to 98.2 mm as compared to non-treated animals in a dose of 0.01 mg/kg, without reducing the infarct volume of the rat brain at dosages >0.01 mg/kg.
Clinical Trial
Molecular Weight

498.57

Formula

C27H34N2O7
CAS No.
SMILES

O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Moexipril Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Moexipril103775-10-6Angiotensin-converting Enzyme (ACE)Apoptosisangiotensin IIhypertensionhydrochlorothiazidemoexiprilathepatic diseaseantihypertensivecardiovascular diseaseIschemic brain injuryorally activeessential hypertensionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Moexipril
Cat. No.:
HY-117281
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.